TMEM38B and osteogenesis imperfecta: Here we used CRISPR/Cas9 to successfully generate the first in vitro osteoblast model for OI type XIV reproducing the molecular and biochemical features of patients’ cells and we demonstrated the negative effect of TRIC-B loss-of-function in osteoblast proliferation and mineralization.